For an estimated 39 million Americans, snoring isn’t just a nuisance, it’s a symptom of a dangerous disorder.

Obstructive sleep apnea is defined by pauses in a person’s breathing while sleeping, which invite a host of health-depleting consequences.

While mechanical and surgical interventions are available, patients currently have no medicinal option. Pharmaceutical company Eli Lilly hopes that will soon change.

New research, funded by the pharma giant and published in The New England Journal of Medicine in late June, shows potential for popular weight-loss and diabetes drug tirzepatide to reduce the severity of moderate-to-severe obstructive sleep apnea, or OSA.

Advertise with us

Marketed as Zepbound for weight loss and Mounjaro for diabetes, the drug has been shown to produce an 18% weight reduction on average. Since excess weight is the number one contributor to obstructive sleep apnea, accounting for about 60% of cases, it’s logical that significant weight loss would also improve OSA, up to a whopping 62.8%, per the study.

Published in the same edition of the NEJM, however, an editorial penned by Sanjay R. Patel, University of Pittsburgh Medical Center Comprehensive Sleep Disorders program medical director, urged caution before kicking traditional OSA treatments to the curb.

“It’s important to put it into context, where this drug can play a role in treating sleep apnea,” Patel said. “There are a lot of people who kind of hype this up to say no one is ever going to use CPAP again, and everyone is going to get their sleep apnea treated with tirzepatide, which I think is very premature.”

CPAP, or continuous positive airway pressure, is the most common treatment for sleep apnea, involving a machine, tubing and a facial apparatus that gently push air into the patient’s mouth and nose, ideally throughout the night, countering the effects of breathing lulls.

But 50% of the time, patients abandon the treatment within three years.

Advertise with us

“If you’re single, and trying to meet people, and bring them home for the first time, yeah, obviously CPAP is a horrible thing to say, ‘Oh, by the way, let me introduce you to this third thing in our relationship,’” he said. “And if you travel a lot, it’s burdensome to carry with you.”

As another potential cause of degraded reliance on the machines, he also cites the recall of popular Philips Respironics CPAP machines, and purported wrongdoing on the part of the company, as exposed by a Post-Gazette and ProPublica investigation beginning last year.

In addition, insurance can complicate patient compliance.

“With CPAP, one of the most bizarre things is insurance companies will revoke coverage for CPAP if you aren’t using it for an arbitrary number of hours, for four hours a night, let’s say,” Patel said. “That doesn’t exist for any other type of treatment,” and it also leads to racial disparities in sleep apnea care.

Black people tend to sleep less, Patel explained. When insurance companies require four hours of use each night, that’s a greater proportion of their sleep time, which places a greater burden on the group to comply.

Advertise with us

Aside from those impediments, Patel regularly encounters enthusiastic patients, and their supportive significant others, who are thrilled to cure the snoring, increase their time asleep and improve their quality of life, both together and separately.

However, those formally diagnosed patients represent only about 20% of those suspected to combat sleep apnea. The other 80% are presumed based on how closely the disorder follows other diagnoses, such as obesity (a 60% to 90% co-occurrence) and diabetes (which co-occurs over 50% of the time).

Despite those comorbidities, many patients still don’t have access to medications such as Mounjaro and Zebound.

An Eli Lilly spokesperson confirmed the submission of tirzepatide for the treatment of moderate-to-severe OSA and obesity to the Food and Drug Administration; submissions to “other global regulatory agencies” are expected over the coming weeks. All are approvals needed to improve financial access to the drugs.

“A lot of the patients with sleep apnea are overweight or have diabetes or prediabetes or high blood pressure. So whether you’re treating them for the sleep apnea or diabetes, it’s going to make all of these things better,” Patel said. “But right now, most insurances are approving it for diabetes but not obesity. If [tirzepatide] does get FDA approval for sleep apnea, and insurances will cover it, that’s another way that a patient who doesn’t have diabetes, but is obese, can get access to the drug.”

Advertise with us

The Eli Lilly spokesperson could neither comment on whether the approval sought will affect Zepbound, Mounjaro or both, nor could they comment on exact timing for the FDA’s decision, but added that the company received FDA Fast Track designation for moderate-to-severe OSA in patients with obesity, which is awarded to interventions that “treat serious conditions and fill an unmet medical need,” per the FDA’s website, and expedites the approval process.

But for Patel, the issue isn’t only FDA approval. It’s his own standard for sufficient evidence.

When Patel diagnoses OSA and pitches the idea of CPAP — or another treatment, such as surgery or dental devices — he doesn’t try to “sell” patients on improving cardiovascular outcomes, such as lowering blood pressure or likelihood of stroke.

To him, it’s unclear whether those risks are directly associated with OSA or other risk factors those patients often have (obesity and/or diabetes), which is why he instead focuses on improved quality of life, which is a place where the recent tirzepatide study falls short, in his opinion.

“As we get more robust data — and I think they have it, they just need to analyze it more — about how it improves symptoms, that will help us, as clinicians, counsel patients on how this drug is going to make them feel versus another treatment option,” he said.

Advertise with us

The Eli Lilly-funded research boasts 51.5% of study participants met criteria for disease resolution.

An separate set of data show that nearly 50% of patients who begin treatment with a GLP-1 receptor agonist for obesity, the drug class that includes tirzepatide and semaglutide (sold as Ozempic), discontinue therapy within one year.

In both cases, a sizable portion of the patient population still struggles with symptom control, and is in need of longterm solutions.

To Patel, that long-lasting care will continue to include CPAP and other traditional interventions, at least for some, which led to his sobering editorial amid the anticipation of an impending novel approach.

“I’m not trying to say this drug isn’t going to be useful. It’s going to be useful, and that’s [Eli Lilly’s] job as a pharmaceutical company, to hype up their product,” he said. “The BMI reduction is real. The blood pressure reduction is real. Those are important things. We just need to be careful about how we spin it.”

Abby Mackey is a registered nurse, and can be reached at amackey@post-gazette.com and IG @abbymackeywrites.